Standard

Inhibitors of DNA glycosylases as prospective drugs. / Mechetin, Grigory V.; Endutkin, Anton V.; Diatlova, Evgeniia A. et al.

In: International Journal of Molecular Sciences, Vol. 21, No. 9, 3118, 28.04.2020.

Research output: Contribution to journal › Review article › peer-review

Harvard

Mechetin, GV, Endutkin, AV, Diatlova, EA & Zharkov, DO 2020, 'Inhibitors of DNA glycosylases as prospective drugs', International Journal of Molecular Sciences, vol. 21, no. 9, 3118. https://doi.org/10.3390/ijms21093118

APA

Mechetin, G. V., Endutkin, A. V., Diatlova, E. A., & Zharkov, D. O. (2020). Inhibitors of DNA glycosylases as prospective drugs. International Journal of Molecular Sciences, 21(9), [3118]. https://doi.org/10.3390/ijms21093118

Vancouver

Mechetin GV, Endutkin AV, Diatlova EA, Zharkov DO. Inhibitors of DNA glycosylases as prospective drugs. International Journal of Molecular Sciences. 2020 Apr 28;21(9):3118. doi: 10.3390/ijms21093118

Author

Mechetin, Grigory V. ; Endutkin, Anton V. ; Diatlova, Evgeniia A. et al. / Inhibitors of DNA glycosylases as prospective drugs. In: International Journal of Molecular Sciences. 2020 ; Vol. 21, No. 9.

BibTeX

@article{2ef545fad7554f298d6eb08e9f248118,
title = "Inhibitors of DNA glycosylases as prospective drugs",
abstract = "DNA glycosylases are enzymes that initiate the base excision repair pathway, a major biochemical process that protects the genomes of all living organisms from intrinsically and environmentally inflicted damage. Recently, base excision repair inhibition proved to be a viable strategy for the therapy of tumors that have lost alternative repair pathways, such as BRCA-deficient cancers sensitive to poly(ADP-ribose)polymerase inhibition. However, drugs targeting DNA glycosylases are still in development and so far have not advanced to clinical trials. In this review, we cover the attempts to validate DNA glycosylases as suitable targets for inhibition in the pharmacological treatment of cancer, neurodegenerative diseases, chronic inflammation, bacterial and viral infections. We discuss the glycosylase inhibitors described so far and survey the advances in the assays for DNA glycosylase reactions that may be used to screen pharmacological libraries for new active compounds.",
keywords = "DNA glycosylases, DNA repair, Drug targets, ESCHERICHIA-COLI FPG, BASE-EXCISION-REPAIR, drug targets, PROINFLAMMATORY GENE-EXPRESSION, VACCINIA VIRUS, SENSITIVE DETECTION, PROCESSIVITY FACTOR, SMALL-MOLECULE INHIBITOR, SIGNAL AMPLIFICATION, SUBSTRATE-SPECIFICITY, PSEUDOMONAS-AERUGINOSA",
author = "Mechetin, {Grigory V.} and Endutkin, {Anton V.} and Diatlova, {Evgeniia A.} and Zharkov, {Dmitry O.}",
note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2020",
month = apr,
day = "28",
doi = "10.3390/ijms21093118",
language = "English",
volume = "21",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

RIS

TY - JOUR

T1 - Inhibitors of DNA glycosylases as prospective drugs

AU - Mechetin, Grigory V.

AU - Endutkin, Anton V.

AU - Diatlova, Evgeniia A.

AU - Zharkov, Dmitry O.

N1 - Publisher Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2020/4/28

Y1 - 2020/4/28

N2 - DNA glycosylases are enzymes that initiate the base excision repair pathway, a major biochemical process that protects the genomes of all living organisms from intrinsically and environmentally inflicted damage. Recently, base excision repair inhibition proved to be a viable strategy for the therapy of tumors that have lost alternative repair pathways, such as BRCA-deficient cancers sensitive to poly(ADP-ribose)polymerase inhibition. However, drugs targeting DNA glycosylases are still in development and so far have not advanced to clinical trials. In this review, we cover the attempts to validate DNA glycosylases as suitable targets for inhibition in the pharmacological treatment of cancer, neurodegenerative diseases, chronic inflammation, bacterial and viral infections. We discuss the glycosylase inhibitors described so far and survey the advances in the assays for DNA glycosylase reactions that may be used to screen pharmacological libraries for new active compounds.

AB - DNA glycosylases are enzymes that initiate the base excision repair pathway, a major biochemical process that protects the genomes of all living organisms from intrinsically and environmentally inflicted damage. Recently, base excision repair inhibition proved to be a viable strategy for the therapy of tumors that have lost alternative repair pathways, such as BRCA-deficient cancers sensitive to poly(ADP-ribose)polymerase inhibition. However, drugs targeting DNA glycosylases are still in development and so far have not advanced to clinical trials. In this review, we cover the attempts to validate DNA glycosylases as suitable targets for inhibition in the pharmacological treatment of cancer, neurodegenerative diseases, chronic inflammation, bacterial and viral infections. We discuss the glycosylase inhibitors described so far and survey the advances in the assays for DNA glycosylase reactions that may be used to screen pharmacological libraries for new active compounds.

KW - DNA glycosylases

KW - DNA repair

KW - Drug targets

KW - ESCHERICHIA-COLI FPG

KW - BASE-EXCISION-REPAIR

KW - drug targets

KW - PROINFLAMMATORY GENE-EXPRESSION

KW - VACCINIA VIRUS

KW - SENSITIVE DETECTION

KW - PROCESSIVITY FACTOR

KW - SMALL-MOLECULE INHIBITOR

KW - SIGNAL AMPLIFICATION

KW - SUBSTRATE-SPECIFICITY

KW - PSEUDOMONAS-AERUGINOSA

UR - http://www.scopus.com/inward/record.url?scp=85083977621&partnerID=8YFLogxK

U2 - 10.3390/ijms21093118

DO - 10.3390/ijms21093118

M3 - Review article

C2 - 32354123

AN - SCOPUS:85083977621

VL - 21

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 9

M1 - 3118

ER -

ID: 24159462